AveXis is a biotechnology company that develops treatments for rare neurological genetic disorders. It was founded in 2015 by Brian Kaspar around a discovery of a novel method of treating spinal muscular atrophy using gene therapy. AveXis was acquired by Novartis in 2018 for USD 8.7 billion.